Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study

PURPOSE: Combined transarterial chemoembolization (TACE) and Lenvatinib (LEN) treatment (LEN-TACE) has been shown to be beneficial. We aimed to evaluate retrospectively Atezolizumab plus Bevacizumab (Atezo/Bev)-TACE compared with LEN-TACE as a first-line therapy for unresectable HCC. PATIENTS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chenghao, Xiang, Zhanwang, Li, Mingan, Wang, Haofan, Liu, Huan, Yan, Huzheng, Huang, Mingsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386869/
https://www.ncbi.nlm.nih.gov/pubmed/37521029
http://dx.doi.org/10.2147/JHC.S418256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386869/
https://www.ncbi.nlm.nih.gov/pubmed/37521029
http://dx.doi.org/10.2147/JHC.S418256

Ejemplares similares